Physician profile
Mikhail Vassilenko
NPI 1053380584
$1,743.40
in general payments reported to CMS, 2019-2025
17 companies · $667 in 2025
The $667 reported for 2025 was more than what 75% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $457 · 2020: $201 · 2021: $207 · 2022: $178 · 2024: $33.41 · 2025: $667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $700.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $395.05 | 2019-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $278.34 | 2019-2025 | Spravato |
| Alkermes, INC. | $241.59 | 2019-2025 | Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $225.51 | 2020-2025 | Caplyta |
| Abbvie INC. | $168.72 | 2025 | |
| Sunovion Pharmaceuticals INC. | $114.12 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $75.12 | 2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $41.88 | 2022-2025 | Fanapt |
| Neurocrine Biosciences, INC. | $38.01 | 2025 | |
| Allergan, INC. | $31.25 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $28.25 | 2025 | Austedo Xr |
| Tris Pharma INC | $23.03 | 2025 | Dyanavel Xr |
| Indivior INC. | $20.98 | 2021 | |
| Almatica Pharma LLC | $19.98 | 2025 | Loreev Xr |
| Acadia Pharmaceuticals INC | $19.97 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $10.90 | 2025 | Azstarys |
| Neuronetics, INC. | $10.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mikhail Vassilenko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.